ERBB2 and breast cancer: Similarly, patients with HER2‐positive BC determined using IHC and/or ISH studies are likely to be offered in anti‐HER2 therapy, regardless of molecular portrait, while it is not current practice to offer this treatment to patients with HER‐2‐positive BC based on molecular portrait alone.